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Abstract: In this review we present our recent contribution to the field of bioorganometallic chemistry of ferrocene. Ferrocene conjugates with 
biomolecules have been synthesized and characterized using IR and NMR (1H, 13C, COSY, NOESY, HMBC) spectroscopy, ESI-MS and HRMS. The 
bioconjugates of ferrocene with resveratrol (2) and mannose (10, 11, 14 and 15) were biologically evaluated for their potential inhibitory effect 
on HepG2 cancer cells (2) and E. coli adherence to the bladder epithelium (10, 11, 14 and 15). The oxalamide-bridged ferrocene 17 was sub-
jected to conformational analysis in solution and in the solid state, and tested for its gelation and cytotoxic activity. The mono- (30–32, 36–38, 
42–45) and disubstituted ferrocene conjugates with natural amino acids (21–28, 33–35, 39–41, 48, 49, 62–65, 69–72) were subjected to the 
detailed conformational and DFT analyses in order to determine the turn-inducing potential of ferrocene scaffolds in the corresponding 
peptidomimetics. 
 






ERROCENE was serendipitously discovered 66 years 
ago when Pauson and Kealy tried unsuccessfully to 
prepare fulvalene (C10H8) by reaction of cyclopentadiene 
bromide with iron (II) chloride. Instead of fulvalene, they 
obtained the orange solid that was consistent with 
molecular formula FeC10H10.[1] A year later, Wilkinson and 
Woodward[2] deduced the real structure of the novel 
compound - [Fe(C5H5)2] - where two anionic cyclopenta-
dienyl (Cp) rings donate 6 π electrons to the Fe2+ cation 
sandwiched between them. Since its reactivity resembles 
that of benzene, the name ferrocene for the novel 
sandwich complex was coined.[3,4] It soon became apparent 
that ferrocene features several types of remarkable 
properties: solubility in common organic solvents, stability 
up to 400 °C, reactivity as a superaromatic electrophile and 
mild and reversible oxidation around +0.4 V vs. saturated 
calomel electrode (SCE) (Figure 1). 
 So far, ferrocenes have been reported in more than 
18000 papers (Web of Science)[5] and as such are 
recognized as an icon of organometallic chemistry. The 
recently published microreview on ferrocenes[5] gives an 
overview of ferrocene applications in fields such as 
nanomedicine, biological sensing (the detection of glucose 
in blood,[6] protein and DNA binding, immunoassay 
tracers,[7] etc.), catalysis, battery and other materials, and 
other areas involving supramolecular, macromolecular, 
and optoelectronic property aspects.  
 Owing to their exceptional characteristics (stability 
in biological media, redox activity, easy penetration 
through cell membrane owing to the lipophilicity, low 
toxicity, feasibility to chemical modification, commercial 
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availability), ferrocenes have attracted much attention in 
the field of medicinal organometallic chemistry termed also as 
bioorganometallic chemistry.[8] Ferrocene compounds have 
been intensively explored for medical purposes,[8] esspecially 
in anticancer[9,10] and antimicrobial studies. Among numerous 
ferrocene compounds tested for their anticancer activity, the 
particular attention has been paid to antiproliferative effect of 
ferrocenyl tamoxifen analogue named ferrocifen, on breast 
cancer cells.[11] The antitumor activity of various bioferrocenes 
such as ferrocenyl alkyl nucleobases,[12] azalactone ferro-
cene,[13] ferrocenyl conjugates with salts of N-alkylpyridin-
ium[14] and carbohydrate ferrocene conjugates[15] was also 
examined. The initial researches of antimicrobial effects of fer-
rocenes began with ferrocene modified penicillins, cephalo-
sporins and rifamycin,[16–19] and continued with derivatives 
containing various pharmacophore groups[20] and structural 
fragments of biomolecules, such as amino acids, peptides, sug-
ars, nucleobases and steroids.[21,22] 
 Considering the biological significance of ferrocene-
modified biomolecules,[11,23–27] the joint research on the man-
noside inhibitors of hemagglutination Ia–c[28] and IIa–c[29] that 
contain ferrocene moiety in aglycon has been started in Rapić 
and Tomić groups (Figure 2). Since the urinary tract infections 
are mostly caused by adhesion of uropathogenic Escherichia 
coli on mannose units of a membrane glycoprotein that is ex-
pressed on superficial epithelial cells of the urinary tract,[30] the 
development of antiadhesion therapeutics aimed to prevent 
Escherichia coli lectin FimH-mediated adhesion has become a 
focus of researches in the last 50 years. The chemical synthesis 
of mannose-containing antiadhesives involves the insertion of 
lipophilic alkyl or aromatic groups to the aglycon part,[31] result-
ing in a dramatic increment of their affinity for FimH. 
Therefore, the significant increment of the inhibitory activity of 
conjugate IIc in comparison to conjugates Ia–c and IIa,b was in 
accordance with the enhanced inhibitory activity of the man-
nosides with elongated alkyl chains.[31]  
 Furthermore, the conjugates of ferrocene and amino 
acids have been extensively studied in the field of pep-
tidomimetics. 1,1′-Disubstituted ferrocene scaffolds, equipped 
with hydrogen bonding functionalities, have been employed 
for almost 20 years to nucleate turns and β-sheet-like struc-
tures in short peptides.[32–37] The two cyclopentadienyl rings in 
ferrocene have a distance of ~3.3 Å which corresponds to the 
space between hydrogen bonding donor and acceptor sites in 
β-sheets. Thereby, the introduction of the peptide chains into 
the ferrocene scaffold brings them to adequate distance to al-
low their communication through intramolecular hydrogen 
bonding required for 3D structure formation and function of 
biological systems.[38] The hydrogen bond donating/accepting 
properties of turn-inducing ferrocene scaffolds determine the 
hydrogen bonding patterning of the derived peptides: the ten-
membered interstrand hydrogen-bonded rings (β-turn-like) 
were established in the conjugates of the amino acids or pep-
tides with dicarbonyl-functionalized ferrocene core (III),[32] the 
twelve-membered rings were formed in their conjugates with 
–NH–Fn–CO– moiety (IV, Fn = ferrocenylene),[33] while conju-
gation with diamino-functionalized ferrocene lead to the four-
teen-membered hydrogen-bonded rings [also labelled as two 
simultaneous ten-membered rings (β-turn-like)] in the corre-
sponding conjugates Va[34] (Figure 3).  
 The overview of the previously reported peptides IV 
was given by Rapić.[39] 
 In this contribution, the review of authors recent 
research results on ferrocene (bio)conjugates is given. The 
 
Figure 2. The mannose-containing ferrocenes I and II. 
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first part of the paper is concerned on potential biologically 
active ferrocene conjugates with resveratrol and mannose. 
The second part of the paper is dealing with conformational 
behaviour of ferrocene peptidomimetics studied by means 
of spectroscopic methods and DFT calculations. 
 
I.  
SYNTHESIS AND BIOLOGICAL 
EVALUATION OF FERROCENE 
CONJUGATES WITH RESEVERATROL  
AND MANNOSE 
Ferrocene-resveratrol Conjugate 2 
Resveratrol [3,5,4'-trihydroxystilbene (RSV) (Figure 4a)] is 
well-known to promote cardioprotection, cancer pre-
vention and therapy, immune regulation and metabolic and 
neuroprotective functions.[40–42] The approaches for im-
proving its biological profile include modification of the 
number and position of the aromatic groups, insertion of a 
long alkyl chains or functionalized chains and the addition 
of acyl chains to free hydroxyl groups.[43] Vervandier-
Fasseur et al. applied the first approach to prepare 
ferrocene-containing RSV-derivative VI that was found to 
exibit more than 10-fold higher inhibitory activity in 
primary human colon carcinoma cells (SW480) and 
hepatoblastoma (HepG2) cell lines compared to those of 
RSV (Figure 4b).[44] 
 Encouraged by this result, we have synthesized 
ferrocene-RSV conjugate 2 equipped with trimethylene 
alkyl chain in order to improve its lipophilicity as a crucial 
requirement for biological activity.[45] The conjugate 2 was 
obtained by esterification[46] of ferrocene butyric acid (1) 
with C3–OH group of trans-RSV in the presence of DMAP, 
NEt3 and Boc2O (Scheme 1) and its inhibitory potential on 
HepG2 and normal ovary cells (CHO-K1) proliferation was 
evaluated. 
 The results of cytotoxicity evaluation revealed 
profound effects in biological activity of ferrocene-RSV 
conjugate 2 vs. RSV in HepG2 cell line (Figure 5). 
Accordingly, IC50 value for 2 was 20 % lower than IC50 value 
for RSV. Much lower cytotoxicity on normal CHO-K1 cells 
was observed. In spite of the decreased activity in 
comparison to the previously reported conjugate VI[44], our 
conjugate 2 was more potent than RSV and therefore 
indicated the potential for further studies on ferrocene-
RSV conjugates that are in progress in our group. 
Ferrocene-mannose Conjugates  
10, 11, 14 and 15 
The improved biological activity of the previously reported 
conjugate IIc[29] was attributed to the elongation of the 
alkyl spacer incorporated between ferrocene core and 
chiral linker. Besides the elongated aglycon alkyl chain,[47] 
the two structural elements - mannose moiety and 
hydrophobic aglycon residue - are required to achieve the 
antiadhesion effect. Considering these findings, we were 
prompted to determine if the further elongation of the alkyl 
chain from propyl to pentyl in bioorganometallics 10, 11, 14 
and 15 will contribute to their pronounced inhibitory 
effect.[48] The novel bioconjugates were designed to 
contain ester (10, 11) or amide linkage (14, 15) between 
 
Figure 4. The chemical structures of (a) resveratrol (RSV) and (b) ferrocene-RSV analog VI. 
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mannose and ferrocene in order to obtain a set of 
compounds that enables the more precise evaluation of the 
structural requirements for higher binding affinity of 
ferrocene-containing inhibitors of hemagglutination. 
 The condensation of the organometallic moieties 
with mannopyranoside acid was realized through ester and 
amide bonding, respectively (Scheme 2). The esterification 
of the mannopyranoside acid 7α,β with ferrocene alcohols 
3 and 4 in the presence of stoichiometric amount of Boc2O 
and catalytic amount of DMAP gave O-protected ester 
conjugates 8α,β and 9α,β. The synthetic pathway to obtain 
amide conjugates 12α,β and 13α,β started by Boc-
deprotection of carbamates 5 and 6 in acidic milieu. The 
obtained hydrochloride salts were treated with an excess 
of NEt3 to liberate free amines available for coupling with 
previously activated acid 7α,β to give O-protected amides 
14α,β and 15α,β. Considering the α-anomeric preference 
of bacterial lectin FimH, the anomeric mixtures of the 
synthesized bioconjugates were separated by preparative 
thin layer chromatography and α-anomers of ferrocene 
conjugates with mannose were subjected to debenzylation 
to give goal compounds 10α, 11α, 14α and 15α. The next 
step was to evaluate the minimal concentration of the 
synthesized bioconjugates required to prevent FimH-
mediated agglutination of guinea-pig erythrocytes, that 
was expressed as inhibition titer (IT) and compared to those 
of a reference inhibitor, methyl α-D-mannoside (MeMan) to 
give relative IT (RIT). Although we have already observed 
that the elongation of the alkyl chain in compound IIc was 
accompanied with the increment of the inhibitory 
activity,[29] the herein obtained results revealed that the 
alkyl chain length is not of decisive importance for FimH-
mediated binding of the investigated ferrocenes 10α, 11α, 
14α and 15α. Since the compound 15α displayed 2-fold 
increment of inhibitory activity in comparison with herein 
studied compounds and 14-fold increment in comparison 
to standard MeMan (Figure 6), it is more likely that 
replacement of an ester linkage in 10α with amide linkage 
in 15α (both containing butyl spacer between ferrocene 
moiety and linkage) strongly influences the inhibitory 
potential.  
 Our ongoing research is directed to explore if the 
aromatic modification of the most potent FimH antagonist 
15α will improve lipophilicity and binding affinity in the 
hydrophobic cavity of the mannose binding site of FimH, 
founded to be flanked with aromatic tyrosine residues. 
 
II. 
CONFORMATIONAL PROPERTIES OF  
FERROCENE PEPTIDOMIMETICS  
Oxalamide-bridged Ferrocene 17 
Peptides experience serious challenges (low metabolic 
stability towards proteolysis, the poor membrane 
permeability and the interactions with undesired receptors 
due to their conformational flexibility) on their way to 
become applicable for medicinal purposes. These obstacles 
can be overcome by using peptidomimetics.[49,50] Among 
the numerous approaches in the design and synthesis of  
 
Figure 5. In vitro anti-proliferative effect of RSV and ferrocene-RSV conjugate 2 against (a) hepatoblastoma (HepG2) cells and 
(b) normal ovary cells (CHO-K1). 
 
Figure 6. Inhibition of hemagglutination of guinea-pig 
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peptidomimetics, the replacement of the peptide bond 
with other chemical groups[51] or partially retro or retro-
inverso modifications[52,53] has been drawing attention. The 
retro-peptides, including oxalamide based retro-peptides, 
represent a valuable class of peptidomimetics owing to 
their improved proteolytic stability and bioavailability in 
comparison to the original peptides. Besides their 
application in bioorganic and medicinal chemistry[54] as 
anticancer agents,[55–57] antimalarial agents,[58] and inhibit-
ors against Alzheimer’s disease[59] and HIV-1,[60] the oxal-
amide moities were used in engineering and crystal 
design,[61] in coordination chemistry as ligands[62] and in 
organogels formation.[63]  
 The extensive work of Žinić and co-workers on 
oxalyl-retro peptides gelators[63] revealed that intramolec-
ular hydrogen bonds determine the conformation, while 
intermolecular hydrogen bonding is mostly responsible for 
supramolecular organization of the oxalamides.[64–66] 
 With this in mind, we have synthesized oxalamide-
bridged ferrocene 17 (Scheme 3), and have tested its 
cytotoxic and gelation potential.[67] Boc-deprotection of 
compound 16 in the presence of gaseous HCl, followed by 
treatment of the hydrochloride salt with NEt3 gave free 
amine. The addition of oxalyl-chloride enabled the bridging 
of the two ferrocene moieties by oxalamide unit. 
 Considering that gelation is governed by hydrogen 
bonding, we took IR and NMR spectroscopic studies in  
order to elucidate the hydrogen bonding behaviour of the 
compound 17. The involvement of amide protons in 
hydrogen bonds is implied by red shifted NH stretching 
vibrational frequencies observed at 3369 cm–1 and 
corroborated by their downfield shift (δ = 8.56 ppm) in non-
polar CDCl3. The nature of the hydrogen bonding was 
tentatively deduced by measuring concentration-
dependent IR and NMR spectra. Since IR absorption 
frequency and NH chemical shift were almost preserved 
upon dilution, the intramolecular nature of the associated 
NH groups was strongly suggested and endorsed by the 
negligible dependence of the chemical shifts on temperature. 
Thereat, the NOE contact between NHFn and MeCOOMe might 
account for conformational pattern based on NHFn⋅⋅⋅OCCOOMe 
intramolecular hydrogen bonds (IHBs) (Figure 7). 
 In the crystal packing of oxalamide 17, determined by 
single-crystal X-ray diffraction analysis, molecules were not 
connected by the two N–H···O hydrogen bonds as it is common 
for the central oxalamide bridge. Instead, two neighbouring 
molecules were connected by only one N–H···O hydrogen 
bond and two weaker C–H···O hydrogen bonds (Figure 8a). 
In this way molecules made a staircase-like pattern (Figure 8b). 
 Next, the capacity of oxalamide 2 to form gels with 
water and a series of common organic solvents (EtOH, THF, 
CH3CN, acetone, AcOEt, CH2Cl2, toluene, p-xylene, decaline, 
tetraline) and solvents mixture (DMSO-H2O, DMF-H2O) of dif-
ferent polarity was investigated. Instead of gelation only the 
crystallization of compound 17 occurred, despite the fact 
that all the necessary conditions for gelation[68] [an appropri-
ate solubility, the presence of hydrophilic (oxalamide) unit 
and hydrophobic (ferrocene) moiety] were met. Since the 
tested compound did not exhibit any gelation ability, we are 


























Scheme 3. Synthesis of oxalamide-bridged ferrocene 17. 
 
Figure 7. The NOE connectivity between NHFn and MeCOOMe 
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 In vitro screening of oxalamide 17 revealed pro-
liferative as well as cytotoxic effect on normal human 
embryonic kidney cells (HEK293T) and tumour HepG2 cells 
(Figure 9). The observed dual effect of oxalamide 17 is 
attributed to the biological phenomenon named hormesis, 
that is characterised by a low dose stimulation or beneficial 
effect and high-dose inhibition or toxic effect.[69–70] Biphasic 
dose-response effect had not been reported for ferrocenes 
yet. The cytotoxic i.e. antiproliferative activity of the 
oxalamide-bridged ferrocene 17 on the normal HEK293T 
cell line was weaker than in HeLa cancer cell line, whilst the 
displayed proliferative effect was most pronounced on 
normal HEK293T cells, and was not observed in tumour 
HeLa cells. These findings implicated the therapeutic 
potential of oxalamide-bridged ferrocene 17, either as an 
anticancer agent, or as a stimulator of cell growth. 
 
Figure 8. Crystal packing of oxalamide 17. (a) Two C–H···O and one N–H···O hydrogen bonds connect the neighbouring 





Figure 9. Effect of oxalamide-bridged ferrocene 17 on 
HEK293T, HeLa and HepG2 cell viability. The lines 
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carboxylic Acid and Proline 21–24 
Besides its ability to induce turn structures when incor-
porated in peptides,[71–73] proline undergoes cis-trans 
isomerization, a process that regulates numerous biological 
events such as cellular uptake, oligomerization, folding and 
catalysis. Therefore, in continuation of our work on 
ferrocene peptides IV we were interested to determine the 
impact of proline unit on conformational and biological 
properties of the bioorganometallics 21–24.[74] 
 Ac–NH–Fn–CO–Pro-OMe (21) and Boc–NH–Fn–CO–
Pro–OMe (22) were prepared by coupling of N-protected 1'-
aminoferrocene-1-carboxylic acid (19/20) with C-protected 
proline following the above described coupling procedure. 
Boc–Pro–NH–Fn–COOMe (23) and Ac–Pro–NH–Fn–COOMe 
(24), with an exchanged sequence of constituent amino acid 
relative to 21 and 22, were prepared from Boc–NH–Fn–
COOMe (16). Upon Boc-deprotection and coupling with 
activated Boc-Pro-OH the goal compound 23 was obtained. Its 
Boc-group was transfered to Ac giving Ac–Pro–NH–Fn–
COOMe (24) (Scheme 4). 
 Proline-containing bioconjugates 21–24 were sub-
jected to standard spectroscopic methods (IR, NMR and CD 
spectroscopy) to explore their conformational behaviour. 
The amide stretching regions of the IR spectra indicated the 
presence of both associated (bellow 3400 cm–1) and free 
states (above 3400 cm–1). It is evident from the Figure 10a 
that (i) the population of hydrogen-bonded NH groups of 
peptides 21, 22 and 24 is increased in comparison to peptide 
23, and (ii) the intensities of hydrogen-bonded NH 
absorption bands of analogues 21–24 in relation to their free 
NH band depended on the employed blocking group. 
Thereat, the reduced content of the associated NH bands 
was observed for peptides 22 and 23, due to the steric 
hindrance imparted by bulky Boc groups. To access whether 
the hydrogen-bonded NH groups were engaged in intra- or 
intermolecular manner, the concentration dependence of 
NH absorption bands was tested. The unchanged ratio of the 
associated and free NH bands upon successive dilution 
suggested the intramolecular employment of NH groups.  
 Hydrogen-bonding behaviour of bioconjugates 21–24, 
predicted by IR data, was corroborated by the downfield shifts 
(δ > 7 ppm) of their NH groups in non-polar CDCl3. The almost 
preserved amide chemical shifts upon dilution from 50 mM to 
6.25 mM or heating from 258 K to 328 K strongly support the 
intramolecular hydrogen bonding patterning, suggested by 
concentration-independent IR measurements. In order to 
evaluate the strength of IHBs, DMSO titration experiments 
were carried out (Figure 10b). The most downfield shifted 
NHFca of 24 exhibited the lowest sensitivity to DMSO and 
therefore was considered to be involved in a strong IHB. More 
pronounced changes of amide shifts in the presence of DMSO 
were observed for 21 and 23, indicating their engagement in 
IHBs of medium strength. Since the most upfield shifted NHFn 
of 22 was found to be the most DMSO-sensitive, its partici-
pation in a weak IHB was suggested. 
 The NMR data obtained upon heating or DMSO 
titration revealed cis/trans isomerization of proline peptide 
bonds. The complete coalescence of the two peaks that 
correspond to cis and trans isomers occurred upon heating 
from 258 K to 328 K due to the medium (23) and rapid (21, 
22 and 24) isomerization. The abundance of trans amide in 
peptide 24 upon titration with DMSO corroborated the 
assumption of its involvement in strong IHB that induced 
the isomer locking, while the complete coalescence of 
amide resonances of peptide 22 was caused by 
engagement of NH group in weak IHB, as it was suggested 
by its pronounced upfield shifting in the presence of DMSO. 
 
Figure 10. (a) The NH stretching vibrations in concentration-dependent IR spectra of 21–24 in CH2Cl2 (c = 5 × 10–2 M),  
(b) Solvent dependence of NH chemical shifts at varying concentrations of d6-DMSO in CDCl3 (c = 2.5 × 10–2 M,  
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The IHB patterning of peptides 21–24, proposed by IR and 
1H NMR data, was strongly supported by NOE spectroscopy. 
The interstrand NOE contacts NHFn→CHαPro and 
NHFn→MeCOOMe accounts for NHFn⋅⋅⋅OCPro IHB in peptides 21 
and 22, while intrastrand NOE contacts of NHFn with N-
terminal protons of 23 and 24 point to NHFn⋅⋅⋅OCPro IHB (7-
membered γ-turn) (Figure 11). 
 The previous work on ferrocene-containing peptides 
revealed that the insertion of ferrocene chromophore (λ ~ 
480 nm) into the chiral peptide environment enables 
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hydrogen bonding between podand peptide chains. Confor-
mational changes, promoted by insertion of organometallic 
template into peptide chain, lead to the adoption of ordered 
structures that induce Cotton effect in ferrocene region. 
 The absolute values of Cotton effects of 21-24, 
ranged between 500 and 1000 deg cm2 dmol–1 
corresponded to those observed for their alanine 
analogues,[33b] indicating the presence of an ordered 
structures in CH2Cl2 (Figure 12). To address the assumption 
that peptide 22 was involved in the weakest IHB in 
comparison to peptides 21, 23 and 24, their CD activity in 
the presence of DMSO was tested. As expected, the 
absence of Cotton effect was observed for peptide 22, due 
to the cleavage of weak IHB and loss of chiral organization. 
 The intrastrand hydrogen bond in peptide 23, 
predicted by NMR study, persisted in the solid state as well. 
Its conformation was stabilised by one N–H⋅⋅⋅O and four 
weak C–H⋅⋅⋅O intramolecular hydrogen bonds (Figure 13a). 
An additional stabilization was achieved through interchain 




Figure 11. The interchain NOE connectivities between the C– and N–termini of 21 and 22 and the intrachain NOE connectivities 
of 23 and 24 (the proposed IHBs are depicted with dashed lines). 
                    
Figure 12. Cotton effects in chirality-organized ferrocene peptides 21–24 in CH2Cl2 [() c = 1 × 10–3 M)] and CH2Cl2 (c = 1 × 10–
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 The anticancer potential of peptides 21–24 was 
tested in vitro and evaluated on the basis of their ability to 
inhibit growth of MCF7 and HeLa carcinoma cells. While the 
50 % inhibition of cell growth was not detected by the 
compounds 21, 23 and 24, the peptide 22 exhibited the 
highest cytotoxicity in MCF7 and HeLa cells (Figure 14). 
Taking into account the lipophilicity as an important 
requirement in drug design, the obtained results might be 
attributed to the increased lipophilicity of peptide 22 (Rf = 
0.50) in comparison to more polar analogues 21 (Rf = 0.30), 
23 (Rf = 0.33) and 24 (Rf = 0.22). 
Bioconjugates of 1'-Aminoferrocene-1-
carboxylic Acid and Alanine 25–28 
The synthesis of bioconjugates 25–28[75] (Scheme 5) has 
been performed by using the synthetic protocol described 
above for the preparation of proline-containing ferrocenes, 
with aim to obtain the simplest models to study the 
influence of the backbone chirality and terminal group 
bulkiness on conformational properties of ferrocene-
containing peptides. 
 The synthesized bioconjugates were subjected to 
detailed conformational analysis (IR and NMR spectroscopy 
and DFT study) in order to explore if the replacement of the 
bulky Boc group with Ac function and L- to D-Ala exchange 
affects their conformational behaviour.  
 The ratios of free and associated NH bands in IR 
spectra of the examined compounds indicated the 
increased fraction of hydrogen bonded NH groups in Ac-
peptides 27 and 28, most likely owing to steric hindrance of 
Boc groups in 25 and 26. Results from the dilution 
experiments revealed the weakening of the both signals 
corresponding to free (~3424 cm–1) and bonded (~3300 
cm–1) NH groups and appearance of a single band slightly 
shifted to ~3400 cm–1 (Figure 15a), thus disabling reliable 
determination of the character of association. 
 The resonances of NHFn groups of peptides 25–28 
and NHAla groups of Ac-peptides 27 and 28 were observed 
at downfield region and were therefore expected to be 
involved in HB. The upfield shifted NHAla groups of Boc-
peptides 25 and 26 corroborates the assumption that 
hydrogen bonding was somewhat difficult in the presence 
of Boc group. To elucidate the possible intramolecular 
nature of hydrogen bonds, concentration- and 
temperature-dependent NMR spectra were measured, 
without expecting any discernible changes in chemical 
shifts of amide protons engaged in IHBs. The observed 
negligible dependence of the chemical shifts on 
concentration and temperature (Figure 15b) strongly 
      
Figure 13. (a) Conformation of Boc–Pro–NH–Fn–COOMe (23) in the crystal stabilised by intrachain 7-membered IHB-ring  
(γ-turn), (b) an additional stabilization of Boc–Pro–NH–Fn–COOMe (23) through interchain intramolecular dipolar interaction. 
(a) (b)
 
Figure 14. Effects of peptides 21–24 on (a) MCF7 and (b) 
HeLa cells viability. The lines connecting the measured 
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supported the intramolecular hydrogen bonding behavior. 
Furthermore, an increased temperature dependencies of 
concentration-independent NHFn [25 (–5.6 ppb/K), 26 (–6.0 
ppb/K), 27 (–9.6 ppb/K), 28 (–9.6 ppb/K)] and NHAla [27 (–6.4 
ppb/K), 28 (–7.2 ppb/K)] reflected initially shielded states 
transferred to unshielded environment by unfolding of 
conformations organized through IHBs.  
 Evaluation of hydrogen bond strength was carried 
out by DMSO titration. Rapid rise in the slope of the 
titration curves in the region below 20 % DMSO was caused 
by significant changes in chemical shifts (Δδ > 1 ppm) over 
the range of the 1H NMR experiment, owing to participation 
of NH groups in weak IHBs (Figure 15c).  
 The position of hydrogen bond donating and 
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accepting groups in peptides 25–28 allowed the formation 
of both inter- and intrastrand IHBs. The interstrand 
contacts between C- and N-termini required for turn 
formation[76] were observed in NOESY spectra of the 
examined compounds [tBuBoc→MeCOOMe (25/26) and 
MeAc→MeCOOMe (27/28)] and might account for 
NHAla⋅⋅⋅OCCOOMe IHB. Regarding the intrastrand IHBs, the 
NOE contacts NHFn→ MeAc in spectra of Ac-peptides 27 and 
28 were detected, while the contacts of NHFn and protons 
of tert-butyl group in 25 and 26 were not observed, due to 
the absence of hydrogen bonding along the corresponding 
strand. Besides that, the larger frequency of NOE contacts 
for NHFn in Ac-peptides 27 and 28 in comparison to those of 
NHFn in Boc-peptides 25 and 26 additionally supported the 
assumption of steric hindrance imposed by tert-butyl group 
(Figure 16). 
 
Figure 15. (a) The NH stretching vibrations in concentration-dependent IR spectra of 25 and 27 in CH2Cl2, (b) Temperature 
dependence of NH chemical shifts (c = 2.5 × 10–2 M) in the temperature range of 298–328 K, (c) Solvent dependence of NH 
chemical shifts at varying concentrations of d6-DMSO in CDCl3 (c = 2.5 × 10–2 M, 298 K) to probe exposed vs. hydrogen-bonded 
amides, (d) Cotton effects in chirality-organized ferrocene peptides 25–28 in CH2Cl2 (c = 1 × 10–3 M). The compatible results on 




550 M. ČAKIĆ SEMENČIĆ, L. BARIŠIĆ: Ferrocene Bioconjugates 
 




 These assumptions about IHB patterning were 
confirmed with CD signals in the region of ferrocene 
chromophore (Figure 15d). Mirror image arrangement of 
the CD curves of 25 and 26 as well as 27 and 28 resulted 
from their conformational enantiomeric relationship. Due 
to our previous findings,[33] the positive Cotton effects of 
(R)-25 and (R)-27 were attributed to the helices of (P)-
orientation, while corresponding enantiomers (S)-26 and 
(S)-28 adopted an opposite (M)-oriented helices. 
 In our research on ferrocene-containing peptides, an 
experimental data were usually augmented with molecular 
modeling studies to obtain a detailed picture regarding 
hydrogen bonding. The complete conformational analysis 
of Boc-peptide 25 and Ac-peptide 27 was performed using 
combination of molecular mechanics and DFT calculations. 
Relative distribution of conformers for peptides 25/27 with 
L-Ala moieties was the same for their enantiomers 26/28 
with D-Ala. The pseudo-torsion angle defining helicity was 
opposite in pair of enantiomers (for example, one 
enantiomer has (P)-1,2’ and the other (M)-1,5’ config-
uration), while the hydrogen bonding pattern was the 
same, as the molecular geometry of one enantiomer is only 
the mirror image of the other. 
 The DFT analysis results that predicted three IHB 
motifs A–C were compatible with NMR data (Figure 17). The 
most stable conformers of 25 and 27 were found to adopt 
NHFn⋅⋅⋅OCBoc/Ac intrastrand IHB forming 7-membered ring 
[(γ-turn), (type A)] or NHFn⋅⋅⋅NAla intrastrand IHB forming 5-
membered ring of the type B. In the ensemble of the most 
stable conformers, single interstrand NHAla⋅⋅⋅OCFn IHB of the 
type C was observed only in Ac-peptide 27. The same 
observations were valid for their enantiomers 26 and 28. 
Bioconjugates of 1-Acetyl-1’-
aminoferrocene with Amino Acids  
(33–35, 39–41) and Their 
Monosubstituted Analogues  
(30–32, 36-38) 
Bioconjugates 33–35 (Boc–AA–NH–Fn–COMe; AA = Gly, L-
Ala, L-Val)[77] and 39–41 [Boc–(AA)2–NH–Fn–COMe; AA = Gly, 
L-Ala, L-Val][78], derived by N-terminal elongation of Boc–NH–
Fn–COMe, can also be considered as nonsymmetric 
analogues of ferrocene-containing peptidomimetics IV 
(Scheme 6). These derivatives were subjected to detailed CD, 
IR and NMR spectroscopic analysis, combined with 
theoretical investigation (DFT), to describe their preferred 
conformations in solution. Furthermore, to gain better 
insight on the hydrogen bond patterns in 33–35 and 39–41, 
a complete set of their monosubstituted analogues 30–32 
(Boc–AA–NH–Fn; AA = Gly, L-Ala, L-Val) and 36–38 [Boc–
(AA)2–NH–Fn; AA = Gly, L-Ala, L-Val] was synthesised and 
subjected to conformational analysis as well. 
 
Figure 16. (a) The interchain NOE connectivities between C- and N-termini of 25-28 and (b) intrachain NOE contacts for NHFn in 
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 The downfield resonance of NHFn (~7.7 ppm), 
observed in the NMR spectra of 30-35, indicated its 
participation in a hydrogen bond. Although the NHAA 
resonances were registered at high field (5.1 – 5.5 ppm), we 
did not exclude the possibility of involvement of these 
groups in hydrogen bonding due to examples of urethane 
NH groups resonating at high field in CDCl3,[79,80] During 
NMR dilution experiments in the concentration range of  
1.5 – 100 mM any significant variation of NHFn resonances 
was not observed (Δδ < 0.2 ppm), so we attributed the 
initial chemical shift to intramolecular hydrogen bonding. 
Furthermore, to determine the strength of bonds involving 
NH group directly attached to ferrocene, we performed 
DMSO titration experiments. As can be seen in Figure 18, 
the gradual addition of DMSO (from 0 to 30 % in CDCl3) 
caused the dramatic downfield shift of NHFn protons of 32 
 
Figure 17. The intramolecular hydrogen bonding patterns observed in the ensemble of the most stable conformers based on 
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(1.22 ppm) and 34 (1.41 ppm), suggesting that these bonds 
are easily disrupted by the presence of competitive solvent. 
Similar solvent accessibility was observed for NHAA group. 
 Furthermore, large temperature coefficients of 
NHFn protons in disubstituted conjugates (Δδ/ΔT = –4.67, 
–4.67, and –6 ppb K–1 for 33, 34, and 35, respectively) 
were indication of an initially shielded NH groups 
which become exposed with increasing of temperature 
(Figure 18c). 
 The hydrogen-bond patterns found in the most stable 
conformers of 30–35, derived from the computational study, 
are shown in Figure 19. The results of DFT study were in 
accordance with those derived from NMR measurements; in 
minimal energy conformer of all derivatives, NH group 
directly attached to the ferrocene was involved in a hydrogen 
bond with urethane carbonyl. Disubstituted conjugates (33–
35) were additionally stabilized by an interchain bond 







Figure 18. Solvent dependence of NH chemical shifts of compounds (a) 32 and (b) 34 at varying concentrations of d6-DMSO in 
CDCl3 (c = 2.5 × 10–2 M, 298 K) to probe exposed vs. hydrogen-bonded amides, (c) Temperature dependence of NHFn and NHAla 

























Figure 19. The intramolecular hydrogen bonding patterns observed in the most stable conformer based on computational study 
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 NOESY experiments and CD spectroscopy provided 
further evidence for interchain interactions in the 
disubstituted conjugates 33–35. “Superimposable” orient-
ation of substituents on cyclopentadienyl rings rings, 
caused by interstrand bonding, was supported by 
observation of NOESY cross-peaks shown on Figure 20 for 
derivative 35. The visible regions of CD-spectra of chiral 
derivatives (31, 32, 34 and 35) are shown in the same 
Figure. Monosubstituted conjugates 31 and 32 exhibited a 
weak signal near UV/Vis absorption maximum of the ferro-
cene chromophore (MΘ = 683 and –133 deg cm2 dmol–1), as 
expected for derivatives unable to form interchain 
hydrogen bonds.[81] Medium-intensity CD-signals, observed 
in the spectra of 34 and 35 (MΘ = 2751 and 1953 deg cm2 
dmol–1), indicated an ordered chiral environment in the 
vicinity of ferrocene moiety arised from interstrand 
hydrogen bonding. The sign of Cotton effect founded in CD 
spectra of 34 and 35 was in accordance with previously 
described literature examples where bioorganometallics 
derived from L-amino acids exhibited positive CD signals, 
induced by P-helicity of energetically accessible con-
formers[33b,74,75] 
 Peptides 36–41 were synthesised by N-terminal 
elongation of their lower homologues 30–35 and subjected 
to conformational analysis using IR and NMR spectroscopic 
techniques in combination with DFT calculations. In the 
solution IR spectra of all compounds signals belonging to 
hydrogen-bonded NH groups together with signals above 
3440 cm–1 due to presence of free NH groups were 
observed. We ruled out the possibility of intermolecular 
hydrogen bonding by performing IR-dilution experiment, 
over a concentration range of 50 to 0.5 mM (Figure 21a). 
Next, we undertook NMR study to find out which NH 
groups participate in hydrogen bonds as suggested by IR-
spectroscopy. Involvement of NH attached to the ferrocene 
moiety in a hydrogen bond was indicated by its downfield 
shifted signal (~8.1 ppm) in spectra of all conjugates. In 
contrast, signals of NHAA1 as well as the NHAA2 were 
registered at ~6.8 and ~5.2 ppm, indicating that former NH 
group equilibrates between bonded and non-bonded 
states and later does not participate in hydrogen bonds. 
Furthermore, in all conjugates NHFn and NHAA1 were 
significantly less accessible to the solvent than NHAA2 as 
can be seen from DMSO titration experiments, shown on 
Figure 21b. 
 In order to determine the dominant conformations 
of 36–41 in solution, search of the conformational space at 
the B3LYP/6-311 (+G(d,p) and LanL2DZ for iron) level of 
theory was performed. According to computational 
analysis, the lowest energy conformer of monosubstituted 
derivatives 36–38 was stabilized by β-turn-like structure i. 
e., 10-membered hydrogen-bonded ring formed between 
the NH group closest to the ferrocene unit and the 
urethane carbonyl group (Figure 22). This finding was in 
agreement with the results obtained from NOE exper-
iments. As can be seen in Figure 22, sequential dNN (i, i + 1) 
and dαN (i, i + 1) connectivities, characteristic for β-turn, 
were observed in the NOESY spectra of conjugates 36–38. 
 Furthermore, an ordered environment in the vicinity 
of ferrocene chromophore gave rise to a strong signal in CD 
spectra of chiral derivatives 37 and 38 (Figure 23). These 
results were in contrast with previous examples in which 
strong Cotton effects originate from helically chiral arran-
gements of the ferrocene moiety supported by interchain 
hydrogen bonds between the two podand peptide 
chains.[33b] So, for the first time we demonstrated that a 
transfer of chiral information from a folded peptide chain 
to ferrocene chromophore can also give rise to a strong 
signals around the UV/Vis absorption maximum of the 
ferrocene chromophore (λmax ≈ 455 nm). 
 In the analogous 1-acetyl derivatives (39–41), β-turn-
like structures were destabilized according to comput-
ational study, NOESY and CD experiments. This findings can 
be explained by the fact that heteroannular introduction of  
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Figure 21. (a) The NH stretching vibrations in concentration-dependent IR spectra of 37 and 40 in CH2Cl2 (c = 5 × 10–2 M),  
(b) Solvent dependence of NH chemical shifts of compounds 37 and 40 at varying concentrations of d6-DMSO in CDCl3 (c =  
2.5 × 10–2 M, 298 K) to probe exposed vs. hydrogen-bonded amides. 
 
Figure 22. The most stable conformer and important interactions in NOESY spectrum of 37. 
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an additional hydrogen bond acceptor group (COMe) 
enabled the conjugates 39–41 to form interchain hydrogen 
bonds and to expand their accessible conformational 
space. The hydrogen bond patterns found in the ensemble 
of the most stable conformers based on computational 
study of derivatives 39–41 are shown in Figure 24. 
Bioconjugates of Aminoferrocene with 
Homo- and Heterochiral Pro-Ala 
Sequences (42–45) 
Encouraged by the results of conformational analysis and 
interesting chirooptical properties of 36–38 described 
above, we have synthesized four homo- and heterochiral 
aminoferrocene derived peptides: Boc–AA2–AA1–NH–Fn 
(42, AA1 = L-Ala, AA2 = L-Pro; 43, AA1 = D-Ala, AA2 = D-Pro; 
44, AA1 = L-Ala, AA2 = D-Pro; 45, AA1 = D-Ala, AA2 = L-Pro).[82] 
The prefered conformation, according to thorough 
experimental and theoretical analysis, of homochiral  
derivatives 42 and 43 in solution was β-turn-like structure 
(Figure 25b). As can be seen in Figure 25a, chiral 
information was transferred from this local secondary 
structure to a ferrocene chromophore giving rise to strong 
mirror-image signals in the visible region of the CD spectra 
of enantiomeric 42 and 43.  
 The change of the chirality of the amino acid at the  
i + 1 position (Pro) caused a disruption of β-turn-like 
secondary structure in the derived heterochiral peptides 44 
and 45, as suggested by the CD and NMR spectroscopy 
analysis. Computational study proposed that lowest energy 
conformers of heterochiral derivatives were stabilized by 
two consecutive γ-turns in solution of aprotic solvents 
(Figure 25b). 
 On the contrary, the single-crystal X-ray structures of 
heterochiral Boc–D-Pro–L-Ala–NH–Fn (44) and Boc–L-Pro–
D-Ala–NH–Fn (45) were characterized by the presence of 
10-membered hydrogen-bond ring between NH adjacent 
to the ferrocene moiety and urethane carbonyl group 
(Figure 26). Intramolecular hydrogen bonding supported 
the formation of β-turn structure similar to an ideal type II 
β-turn. The right-handed sense of helical induction was 
observed in the structure of 45 while enantiomeric 44 
favoured left-handed helical conformation. 
 Having in mind the results that clearly showed that 
the transfer of the chiral information from folded peptide 
chain to organometallic chromophore gives rise to strong 
response in the ferrocene region of CD spectra, our current 
research is focused on synthesis, conformational analysis 
and chirooptical properties of bioconjugates with a 
potential to form minimum sized peptide helices. 
 
Figure 23. Cotton effects in chirality-organized ferrocene 
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Biconjugates of Ferrocene-1,1’-diamine 
and Alanine (48 and 49)  
Unlike peptides III and IV that have been widely reported, 
only one paper dealing with two symmetrically 
disubstituted homochiral peptides Fn–(NH–AA–Boc)2 (Va, 
AA = L- or D-Ala), derived from Fn(NHBoc)2, was given by 
Kraatz et al.[34] They have demonstrated that 14-membered 
ring between attached symmetrical peptide chains, very 
similar to those founded in antiparallel β-sheet peptides, 
was formed. Therefore, ferrocene-1,1’-diamine (Fcda) 
scaffold was established as a desired structural 
requirement for turn induction and mimicking the natural 
structure of antiparallel β-sheet. Within our recent 
research,[83] we have designed a synthetic approach to 
unsymmetrically disubstituted and orthogonally protected 
conjugates Ac–Ala–NH–Fn–NH–Ala–Boc (48) and Fn–(NH–
Ala–Ac)2 (49) (peptides of type V), with aim to explore 
whether the replacement of one or both Boc groups of Va 
with sterically less demanding Ac groups in 48 and 49 will 
affect the IHB pattern realized through 14-membered 
NHFn⋅⋅⋅OCBoc IHB ring.  
 The key intermediate 47, containing NH groups 
attached to both Cp rings, was obtained from Ac–Ala–NH–
Fn–COOMe (27).[74] The product obtained upon 
saponification of its ester group was transferred to 
orthogonally protected compound 47 via unstable azide 46. 
Then, acidic Boc-deprotection of 47 and coupling with 
activated Boc–Ala–OH gave orthogonally protected Ac–
Ala–NH–Fn–NH–Ala–Boc (48). Upon (i) Boc-deprotection 
and (ii) Ac-protection in the presence of acetyl chloride,[84] 
Fn–(NH–Ala–Ac)2 (49) was obtained (Scheme 7). 
 The both goal compounds displayed the similar IR 
behavior, based on dominant intramolecular hydrogen 
bonding engagement. Since the ratios of hydrogen-bonded 
and non-bonded NH peak intensities in their IR spectra 
were almost the same, the steric hindrance of Boc group 






Figure 25. (a) Cotton effects in chirality-organized ferrocene 
peptides 42–45 in CH2Cl2 (c = 1 × 10–3 M), (b) β-turn 
structure in the most stable conformer of homochiral 









































Figure 26. The enantiomeric β-turns in the crystal structures of heterochiral peptides 44 and 45. 
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 The concentration-independent NMR data sug-
gested the participation of downfield shifted NHFn of 48 and 
49 in intramolecular HB, while NHAc protons experienced 
upfield shifting upon dilution, probably due to their 
involvement to a lesser extent in intermolecular HB. 
Therefore, the larger temperature dependencies of NHFn 
and NHAc were attributed to unfolding or dissociation of the 
initially shielded states, while the low temperature 
dependence of upfield shifted NHBoc corroborated its non-
involvement in HB (Figure 27a). The titration with 
hydrogen-bond-accepting DMSO did not affect the che-
mical shifts of NHFn protons, suggesting their involvement 
in a strong IHBs. The pronounced changes in chemical shifts 
were observed for NHAc and NHBoc (Δδ > 1.7 ppm), con-
firming the proposed non-hydrogen-bonded state for NHBoc 
as well as involvement of NHAc in a weak HB (Figure 27b). 
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 These results contributed to define the confor-
mational environment based on NHFn⋅⋅⋅OCBoc/Ac IHBs. The 
interstrand NOE contact observed between NHFn linked at 
one Cp ring and tBu group belonging to the chain attached 
to another Cp ring supported the proposed interstrand 
intramolecular hydrogen bonding engagement and the 
presence of 14-membered ring (Figure 28a). 
 The observed strong Cotton effects in the region of 
ferrocene-based transitions around 470 nm supported the 
highly organized chiral surrounding around ferrocene unit. 
Considering that Cotton effect reflects an average of the 
entire molecular population, the prevalence of P-helicity 
was strongly supported. Furthermore, the conservation of 
~ 70 % of CD activity in the presence of 20 % of DMSO was 
an additional confirmation of the involvement of the tested 
peptides in strong IHBs (Figure 28b). 
 The computational study of the bioconjugates 48  
and 49 confirmed the NMR proposed hydrogen bonding 
patterns. Thereat, the interchain NHFn⋅⋅⋅OCBoc/Ac IHBs 
enabled the peptide chain to fold into β-turn-like structure 
(Figure 29). 
 The conformational pattern established in solution 
persisted in the solid state as well and it was accompanied 
by favorable intermolecular hydrogen bonds in the 
formation of infinite zig-zag chains (Figure 30). 
 The ferrocene conjugates 48 and 49 were screened 
in vitro for their potential anticancer activity in HepG2 
human liver carcinoma cells and Hs578T human breast 
cancer cells (Figure 31). Although the both tested 
compounds were founded to adopt the same con-
formational pattern, the peptide 48 displayed the 
improved bioactivity, most likely due to its increased 
lipophilicity (Rf = 0.51) in comparison to the more polar 49 
(Rf = 0.12). 
 
Figure 27. (a) Temperature dependence of NH chemical shifts of peptides 48 and 49 (c = 2.5 × 10–2 M) in the temperature range 
of 298–328 K, (b) Solvent dependence of NH chemical shifts of 48 and 49 at varying concentrations of d6-DMSO in CDCl3 (c = 
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Figure 28. The interchain NOE connectivities between C- and N-termini of 48 (left) and Cotton effects in chirality-organized 
ferrocene peptides 48 and 49 in CH2Cl2 [() c = 1 × 10–3 M)] and CH2Cl2 (c = 1 × 10–3 M) containing 20% of DMSO (- - - ) (right). 
 
 
Figure 29. (a) IHB patterns and (b) optimized geometries of the most stable conformers based on computational study for 
peptides 48 and 49. 
     
Figure 30. A molecular structure of bioconjugate 48 (left) and crystal packing diagram showing intramolecular and 
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Bioconjugates of Ferrocene-1,1’-diamine 
with Homo- and Heterochiral Pro-Ala 
Sequences (62–65 and 69–72)  
Recently, we reported the synthesis of the peptides 62-65 
and 69-72 that contain Ala-Pro sequences coupled to NH-
derivatized cyclopentadienyl (Cp) rings.[36] In order to 
examine the influence of the backbone chirality and N-
terminal groups on conformational properties, the 
synthesized peptides were designed to contain homo- or 
heterochiral Ala-Pro sequences with different N-terminal 
groups i.e. the bulky Boc or sterically less demanding Ac 
functionality. 
 The peptides 62-65 were prepared by using the same 
synthetic approach applied for the synthesis of their lower 
homologues 48 and 49 (Scheme 8), while the symmetrically 
disubstituted peptides 69-72 were prepared following the 
procedure applied for the synthesis of their lower 
homologues Va[34] (Scheme 9). 
 The capacity for turn formation was explored by 
concentration-dependent IR spectroscopy and concentrat-
ion-, temperature- and solvent-dependent NMR studies. 
The distinct bands at ~3430 cm–1 and ~3250-3300 cm–1 in 
solution state IR spectra of the examined peptides 
suggested the presence of both free and associated NH 
groups. The blue-shifted amide I bands (~1710 cm–1) 
observed in IR spectra of Boc-peptides 62, 63 and 72 
suggested the alteration of the conformational properties 
in comparison to Ac-peptides 64 and 65. The relative 
intensities of free and associated amide bands of the tested 
peptides were maintained during dilution, owing to the 
intramolecular engagement of hydrogen-bonded amide 
groups.  
 The two kinds of resonances were observed in NMR 
spectra of the goal compounds: the downfield shifted 
resonances of NHFn groups (δ ≳ 9.2 ppm) that suggested 
their involvement in HB and upfield shifted resonances of 
Ala-NHBoc/Ac (δ ~ 5 – 6.5 ppm) that suggested the lower 
potential to experience hydrogen-bonding.  
 The IR findings on non-involvement of the examined 
peptides in intermolecular aggregation were supported by 
the sharp signals and non-affected (NHFn and Ala-NHBoc) or 
slightly affected chemical shifts (Ala-NHAc) upon dilution up 
to 50-fold (Figure 32a). Furthermore, no significant upfield 
shift of the amide protons was observed upon successive 
heating of 1 mM solutions of the examined peptides in 
CDCl3 in the range of 258–328 K, certainly due to their 
involvement in strong IHBs or non-involvement in hydrogen 
bonding at all (Figure 32b). While the amide resonances 
belonging to the conformers of the homochiral peptides 
remained resolved at increased temperature, the signals of 
heterochiral peptides underwent partial coalescence, 
suggesting conformational differences imparted by 
bacbone chirality. 
 The larger temperature dependencies of the 
concentration-independent NHFn protons of peptides 62–
65 indicated that they were initially shielded owing to the 
hydrogen bonding engagement, but became exposed to 
the solvent upon unfolding of the ordered structures at 
increased temperatures. The distinct conformational 
patterning of homo- and heterochiral peptides was strongly 
suggested by different temperature dependencies (Figure 
32b). The concentration-independent D-Ala-NHAc in 
heterochiral peptides 63 and 65 exibited the larger 
temperature dependencies due to their participation in 
intramolecular hydrogen bonding. At the same time, the 
smaller temperature dependencies of the upfield shifted L-
Ala-NHAc in homochiral peptides 62 and 64 reflect their 
non-involvement in HBs (Figure 33). 
 
Figure 31. In vitro anti-proliferative effect of ferrocene and ferrocene conjugates 48 and 49 against HepG2 human liver 
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 The different conformational behaviour of intra-
molecularly engaged NHFn protons of homo- and heterochiral 
peptides was additionally supported by DMSO titration 
experiments (Figure 34). While the NHFn protons of the 
homochiral peptides 62, 64 and 72 moved slightly downfield 
in the presence of DMSO, the NHFn protons of the 
heterochiral peptides 63 and 65 moved slightly upfield. A 
common feature of their Ala-NHBoc/Ac groups was a solvent 
exposure observable through a high degree of solvent sensitiv-
ity (Δδ ~ 1.28 – 1.9) that emerged from their non-involve-
ment in hydrogen bonding or involvement in only weak hydro-
gen bonds. Moreover, unlike the heterochiral counterparts, 
the portion of the trans/trans conformers of the homochiral 
peptides remained almost unchanged upon addition of DMSO.  
 Although the amide resonances of homo- and 
heterochiral peptides displayed different temperature and 
solvent dependences, their common conformational 
feature was involvement of NHFn protons in IHBs. Bearing 
in mind the number and position of hydrogen-bond 
accepting carbonyl groups, the tentative conformations of 
the examined peptides could, therefore, rely on both intra- 
and interstrand IHBs. The interstrand NOE contacts 
observed in spectra of orthogonally protected peptides  
62 (NHFnb→Ala-NHAc) and 63 (NHFnb→Ala-NHAc and 
NHFna→Ala-NHBoc) corroborated the presence of 
interstrand IHBs. However, the NOE contacts NHFn→MeAc 
and NHFn→Ala-NHAc detected in spectra of symmetrically 
disubstituted Ac-protected peptides 64 and 65, and 
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NHFn→Ala-NHBoc visible in spectrum of symmetrically di-
substituted Boc-protected peptide 72, might account for 
both intra- and interstrand IHBs (Figure 35). 
 The strong positive Cotton effects observed in CD 
spectra of the examined compounds strongly suggested the 
high level of chiral organization i.e. P-helicity, established 
through interstrand hydrogen bonding (Figure 36). The 
different loss of CD activity in the presence of 50 % of DMSO 
indicated the different hydrogen bonds strength. The 
heterochiral peptide 65, founded to be the most solvent-
exposed due to the largest DMSO-induced shift of its amide 
protons, conserved only 35 % of initial CD activity. Similarly, 
the other tested heterochiral peptide 63 maintained 39 % 
of its CD activity. The homochiral peptides 64 and 72 were 
founded to be more stable, preserving 57–89 % of the initial 
CD activity upon addition of 50 % of DMSO.  
 The quite different DMSO-behaviour of concentration- 
and temperature-independent NHFn protons of homo- (62, 64, 
72) and heterochiral peptides (65) implied the different  
 
Figure 32. (a) Concentration dependence of NH chemical shifts of heterochiral peptide 63 and homochiral peptides 64 and 72 
(*residual CDCl3, • trans/cis, cis/trans and cis/cis rotamers), (b) Temperature dependence of NH chemical shifts of heterochiral 
and orthogonally protected peptide 63 and homochiral peptides 64 and 72 (c = 1 × 10–3 M in CDCl3) in the temperature range 
of 258–328 K. The corresponding chemical shift differences (Δδ) are indicated on the right. 
 
Figure 33. Amide temperature coefficients of the homo–
chiral peptides 62, 64 and 72, heterochiral peptides 63 and 
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Figure 34. Solvent dependence of NH chemical shifts of (a) homochiral peptides 62, 64 and 72 and (b) heterochiral peptides 63 
and 65 at increasing concentrations of d6-DMSO in CDCl3 (c = 25 mM, 298 K) to probe exposed vs. hydrogen-bonded amides. 
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conformational patterns established through IHBs of different 
kinds and strength. Considering that the less stable confor-
mations arose if the hydrogen bonds were established within 
the same strand,[74,77] the engagement of DMSO-sensitive NHFn 
of peptide 65 in intrastrand IHBs was strongly suggested. 
 The P-helicity indicated by CD data was also 
determined in the crystal structure of compound 63. The 
two IHBs between the podant peptide strands forming one 
ten-membered (β-turn-like) and one thirteen-membered 












Figure 36. The Cotton effects in chirality-organized ferrocene peptides 62–64 and 72 in solution {CH2Cl2 [(—) c = 1 × 10–3 M), 
CH2Cl2 (c = 1 × 10−3 M) containing 20 % of DMSO (―) and CH2Cl2 (c = 1 × 10−3 M) containing 50 % of DMSO (―)]}. 
   
Figure 37. Conformation of Ac-D-Ala-L-Pro-NH-Fn-NH-L-Pro-D-Ala-Boc (63). (a) top-down view revealing P-helicity and torsion 
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 The DFT study corroborated the different con-
formational behaviour suggested by spectroscopic analyses 
(Figure 38). The homochiral peptides 62, 64 and 72 were 
prone to form simultaneous intramolecular hydrogen 
bonding engagement of NHFn, influenced by the steric 
bulkiness of the N-terminal group. The Ac-derivative 64 
adopted the two thirteen-membered interstrand hydrogen 
bonded rings (pattern B). In the peptides 62 and 72, 
containing one or both bulky Boc-groups instead of Ac, one 
thirteen-membered hydrogen bonded ring was preserved 
while another was replaced with ten-membered ring 
(pattern A). 
 The L- to D-Ala exchange in heterochiral peptides 63 
and 65 strongly influenced their conformational patterning: 
the thirteen-membered ring, most commonly observed in 
the heterochiral counterparts, was replaced by the highly 
symmetrical intramolecular hydrogen bonding pattern 
made of seven-membered intrastrand and sixsteen-
membered interstrand hydrogen bonds (pattern C).  
 Considering the revealed turn-inducing potential of 
Fcda scaffold, our future work will be directed to the 
conjugates of Fcda with biologically valuable branched-
chain amino acids. 
 
CONCLUSIONS 
This review is aimed to underline the biological and 
conformational potential of ferrocene bioconjugates 
synthesized in our group. Although we have been mainly 
focused on the conformational behaviour of ferrocene 
peptidomimetics, the attention was also paid to the 
potentially biologically active ferrocene compounds.  
The biological evaluation revealed both the cytotoxic and 
hemagglutination inhibition potential of ferrocene 
bioconjugates. The conjugation of resveratrol with 
ferrocene was shown to contribute to the improved 
cytotoxicity against liver cancer cells HepG2, whilst 
significantly lower cytotoxicity on normal ovary CHO-K1 
cells was observed. The interesting biological phenomenon 
named hormesis was observed for oxalamide-bridged 
ferrocene which displayed proliferative effect on normal 
kidney HEK293T cells followed with cytotoxic activity 
against tumour cervical HeLa cells. Besides the cytotoxic 
activity, ferrocenes were also tested as inhibitors of FimH-
mediated hemagglutination. Among the so far tested 
ferrocene conjugates with mannopyranoside acid, 
equipped with aglycon alkyl chains of different length (n = 
0–5), the most pronounced increment of inhibitory activity 
was observed for those which contains butyl group.  
 The major part of our research was aimed to study 
the conformational behaviour of ferrocene 
peptidomimetics. For that purpose, three different 
ferrocene scaffolds (–NH−Fn, –NH–Fn–CO– and –NH–Fn–
NH–) were employed to conjugate with various amino acid 
sequences and the obtained peptides were subjected to 
detailed conformational analysis based on spectroscopic 
measurements (IR, NMR and CD) and DFT study. 
 The results of conformational analysis of peptides 
25–28 [Y–L-Ala–NH–Fn–COOMe (25, Y = Boc; 27; Y = Ac) and 
Y–D-Ala–NH–Fn–COOMe (26, Y = Boc; 28; Y = Ac)] suggested 
the presence of intra- [7-membered NHFn···OCAc HB-ring (γ-
turn) and 5-membered NHFn···NAla HB-ring] and interstrand 
IHBs (9-membered NHAla···OCFn HB-ring). The alanine 
chirality was not observed to influence the hydrogen 
bonding patterning, while the presence of Boc group was 
founded to interfere with hydrogen bonding to a lesser 
extent. The results of computational analysis corroborated 
the IHB motifs predicted by experimental data. 
 The medium-strength hydrogen bond, established 
between NHFn and urethane carbonyl, was found in the 
lowest homologues of nonsymmetric ferrocene peptides 
33–35 (Boc−AA−NH−Fn−COMe; AA = Gly, L-Ala, L-Val) and 
their monosubstituted analogues 30–32 (Boc−AA−NH−Fn; 
AA = Gly, L-Ala, L-Val). N-terminal elongation of 30-35 gave 
mono- 36–38 [Boc−(AA)2−NH−Fn; AA = Gly, L-Ala, L-Val] and 
disubstituted ferrocene peptides 39–41 [Boc−(AA)2−NH−
Fn−COMe; AA = Gly, L-Ala, L-Val]. According to 
computational analysis, the lowest energy conformer of 
monosubstituted derivatives 36–38 is stabilized by β-turn-
like structure (10-membered NHFn···OCBoc HB ring). 
 
Figure 38. The intramolecular hydrogen bonding patterns observed in homochiral peptides 62, 64 and 72 (patterns A and B) 
and heterochiral peptides 63 and 65 (pattern C). 62 and 63 (R1 = Me, R2 = OtBu), 64 and 65 (R1 = R2 = Me), 72 (R1 = R2 = OtBu). 




 M. ČAKIĆ SEMENČIĆ, L. BARIŠIĆ: Ferrocene Bioconjugates 567 
 




Additional hydrogen bond acceptor group (COMe) in the 
analogous 1-acetyl derivatives (39–41) enables them to 
form interchain hydrogen bonds and causes the 
destabilization of β-turn structures.  
 While the enantiomeric β-turns were found to be most 
stable conformations of homochiral derivatives Boc−AA2−
AA1−NH−Fn (42, AA1 = L-Ala, AA2 = L-Pro; 43, AA1 = D-Ala, AA2 = 
D-Pro), the change of the chirality of the amino acid at the i + 1 
position of β-turn causes its disruption in the solutions of the 
derived heterochiral peptides 44 (AA1 = L-Ala, AA2 = D-Pro) and 
45 (AA1 = D-Ala, AA2 = L-Pro) as suggested by the CD, NMR 
spectroscopy and theoretical analysis.  
 Ferrocene-1,1’-diamine scaffold was found to induce 
the formation of two simultaneous 10-membered β-turn-like 
structures in peptides Ac–Ala–NH–Fn–NH–Ala–Boc (48) and 
Fn–(NH–Ala–Ac)2 (49), thus replicating hydrogen bonding 
pattern of peptide β-sheets. The same pattern was established 
in the solid state and was corroborated with DFT data. 
 The different conformational behaviour of homo- 
(62, 64 and 72) and heterochiral peptides (63 and 65) 
comprised of –NH–Fn–NH– scaffold and Ala-Pro sequences 
was strongly suggested by spectroscopic analyses and 
corroborated with DFT studies. The Ac-derivative 64 
adopted the two 13-membered NHFn···OCAc interstrand 
hydrogen bonded rings. In the peptides 62 and 72, that 
contain one or both bulky Boc-groups instead of Ac, one 13-
membered hydrogen bonded ring was preserved while 
another was replaced with 10-membered interstrand ring 
(NHFn···OCAla). Upon L- to D-Ala exchange, the 13-membered 
ring, most commonly observed in the heterochiral 
conjugates, was replaced by the highly symmetrical 
intramolecular hydrogen bonding pattern made of two 
pairs of hydrogen bonds, 7-membered intrastrand 
NHFn···OCAla and 16-membered interstrand NHFn···OCAla 
hydrogen bonds. The relationship observed between the 
backbone homo- or heterochirality, the hydrogen bonding 
acceptor ability of the N-terminal groups and the hydrogen 
bonding patterning can be applied to tune the preferred 
hydrogen bonded ring size in the derived peptidomimetics. 
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